BCLS II Equity Opportunities LP 13D and 13G filings for Aeglea BioTherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 06:04 am Purchase | 2022-12-31 | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | BCLS II Equity Opportunities LP | 213,908 8.700% | 100,000 (+87.79%) | Filing |
| 2022-02-14 06:40 am Purchase | 2021-12-31 | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | BCLS II Equity Opportunities LP | 113,908 5.800% | 5,908 (+5.47%) | Filing |